


NEUVOLUTION Inc. PITCH DECK 2023

Transcranial
Magnetic
Stimulation




NEUVOLUTION produces a Transcranial Magnetic Neuromodulation device capable of improving the therapeutic results for Depression, Substance Use Disorder(SUD) and Binge Eating Disorder (BED), compared to all approved by FDA.

It is a mature market taken over by disruptive technology.

Thus,it becomes a life changer for 80 M Americans.

\$20 B MARKET VALUE BUSINESS OPPORTUNITY.

\$ 3 Billion = 3Y Plan.



How we address The Problem?



DEPRESSION:

33 M Americans=Nearly **10% of Americans** suffer from depression.

Depression is extremely common in the U.S. and has reached epidemic levels.

Source: American Journal of Preventive Medicine, NIMH

ADDICTION:

HAS BECOME A PUBLIC HEALTH CRISIS

20.4 M people in the USA were diagnosed with SUD (SUBSTANCE USE DISORDERS) in the past year representing **6.1% of total Population**.

*The opioid overdose crisis killed more than 100,000 Americans in a year .

The overdoses cost the nation an est. \$1 trillion a year.

Source: NIDA(National Institute of Drugs Addictions)



BINGE EATING DISORDER(BED):

28.8 M of American adults suffer from binge eating disorder in their lifetime=**9% of the total population**.

The same neural circuit that overpowers the homeostasis decision maker on addictions is responsible for food craving. Approximately half of the risk for BED is genetic.

More than half of BED patients have comorbid anxiety disorders.

Source: ANAD.ORG



The Solution:

Inhibit such dependence of the neural circuit and to strengthen self-control by Brain plasticity stimulation!

All three conditions partially respond to Transcranial Magnetic Stimulation.

However, *for the first time ever...*

AGAINST **DEPRESSION**, **ADDICTION**,

BINGE EATING DISORDER(BED):

-We reach the deeply located regions

in the brain that overpowers

FREE WILL!!!

-We do that on a focalized manner without surpassing the FDA approved therapeutic parameters.

OUR GROUNDBREAKING TECHNOLOGY

Our TMS Device Prototype Development

Our medical device *really works* and features a pleasant user interface that allows our users to complete rehabilitation sessions from the comfort of their home or safe space through our TMS application.

***GROUNDBREAKING TECHNOLOGY**

***CONVENIENCE**


***AFFORDABILITY**

CREATES A HUGE GAP BETWEEN COMPETITION AND NEUVOLUTION MEDICAL DEVICE.


-ALL PRESENT TRANSCRANIAL MAGNETIC OR ELECTRIC NEUROMODULATION TECHNOLOGY BECOMES FROM NOW ON OBSOLETE AFTER NEUVOLUTION.



WHAT'S OUR MARKET SIZE?




**\$20 BILLION
MARKET
VALUE**



**Total Available Market
82.2 M Americans**

MARKET SIZE IN MILLIONS OF DIAGNOSED PATIENTS



■ DEPRESSION ■ BINGE EATING DISORDERS ■ S.U.D.(Addictions)



Affordable

TRUE GRIT is a unique proprietary magnetic field that finally enables modulation of formerly un-reachable regions on the Brain that control addictions.
Groundbreaking Technology, convenience and affordability creates a HUGE gap between competition and NEUVOLUTION Medical device.

TMS

TMS

Competitive Advantage

- ✓ Enables Modulation on Former Un-reachable regions
- ✓ Depression
- ✓ Drug Addictions(FENTANYL)
- ✓ Binge Eating Disorder(BED)
- ✓ Affordable

Expensive



Competition

- ✗ Enables Modulation on Former Un-reachable regions
- ✗ Depression
- ✗ Drug Addictions(FENTANYL)
- ✗ Binge Eating Disorder(BED)
- ✗ Affordable

***REAL RESULTS**

***AROUND 10%**

**OF THE
CURRENT
TMS PLAYERS
PRICE**

***CONVENIENCE**

Competitive Advantage:
“All present transcranial Magnetic or Electric Neuromodulation Technology becomes, from **now on, obsolete after Neuolution.**”



Go to Market strategy

1st.Year market share Projection: 3% Penetration

Our target market includes:

1. Patients
2. Doctors & nurses
3. Caregivers
4. Insurance companies
5. Hospitals
6. Employers
7. Consumers.

First 18 Months Target Market:


2.46 M Americans

Key Factors that most customers look for in a Medical Device:

1. Usefulness
2. Doctor's advice
3. Insurance coverage;
4. Out-of-pocket Expense
5. Ease of Use
6. Reviews.


Our strategy:

Also consists in being able to rehabilitate in the initial 18 Months 3% of the affected population with any of these three serious health problems, being financially savvy and are compromised to start using new effective medical technologies.



Distribution Channels

Go to Market Strategy





PROTOTYPE EVOLUTION:

1. POC(Proof of Concept) has been established.



2. Stage of continuous improvement of the prototype.


3. Currently in raise equity financing options evaluation.




4. Product Development Phase: Design: Controls & Development Planning ;Inputs;Outputs

Verification; Validation; User Needs;Changes; History File. Risk Manegement:

Build supplier & Partner Network; Relationships; Regulatory submission.





Our Traction

8 Initial Months

March 22' - Oct. 22'

- ✓ -Building the Business Case
-Ideation April 22'
- ✓ -Internal Project Develop. May 22'
- ✓ -Proof of Concept(POC) July 22'
NIH Formal Invitation to participate
in several GRANTS Sep. 22'
- ✓ -Company Formation Oct. 22'
- ✓ -Prototype substantial improvement
Nov. 22'
- ✓ -USPTO Pending Patents:
Far-Field MPT#63,387,693
Neuromod. #63/387,695 Dec. 22'
- ✓ -Market research Dec. 22'

6 Recent Months

Nov. 22' - April 23'

- ✓ -Early Stage considerations:
-Develop Regulatory Plan Nov. 22'
- ✓ -Select Markets of Interest Nov. 22'
- ✓ -Determining US Classification
(510k) FDA Nov. 22'
- ✓ -Assemble team candidates Jan 23'
- ✓ -Secure funding (50K) Jan 23'
- ✓ P&L 23' Budget & 3Y Plan Jan 23'
- ✓ NEUVOLUTION Brand register Jan 23'
- ✓ Contract Manufacturing Initial
Negotiations and Visit Jan 23'
Logistics Initial Negotiations
And Visit Jan 23'
- ✓ Patents Appraisal \$12 USM April 23'
- ✓ Patents PENDING April 23'
- ✓ NIDA BluePrint Semifinal
Stage Selection April 23'
- ✓ 2nd.Round ARPA-H May 23'

9 Further Months

July 23'—March. 24'

HUMAN TRIALS For Depression;SUD &
BED

Contract Manufacturing:

Complex Assembly

Packaging

Design and Development

Human Factors • Human-centered design
incorporates patient and user needs

• Market evaluations & user research

• In-house observation suite

• Formative and summative studies performed

on-site • Risk analysis & regulatory gap analysis •

IEC 62366-1 Compliant HF/UE • ANSI/AAMI HE75

human factors engineering Concept

Development

• Identification of leading technologies through

research • Early definition of white space

through consideration of technical, regulatory,

and business requirements • Cross-functional

teams with diverse industry experience • Rapid

iteration of novel concepts through

brainstorming, sketching, and early CAD

• Navigation and generation of IP on behalf of
client

Plastic Injection Molding

Regulatory

Determining EU Classification

Quality Management System

Implementation

Quality Management

System Structure

*To set up a QMS.

*FDA APPROVAL

Production Batch

Aug.-Sept. 23' = 70,000 Devices

INITIAL SHIPMENTS

Oct.-Dec. 23':

70,000 Devices Initial Batch

\$29.4 USM

Initial 12 Months Revenue
Plan:

\$163.0 M

2nd. Year Plan:\$2.15 B


3rd. Year PLAN:\$3.13 B

BUSINESS MODEL & FINANCIAL PROJECTION:


Extensive experience and continue use of P&L statements that provides a breakdown of all revenues and relevant costs and expenses over a given period.


This important report allows Banks and investors transparency about the business’s total income,Debt load and financial Stability.

NEUVOLUTION Inc. 2023 NEUROMODULATION TRUE GRIT DEVICE P&L														*In USD	
P&L - USD															
2023 BUDGET															
	ACTUAL January	BUDGET February	BUDGET March	BUDGET April	BUDGET May	BUDGET June	BUDGET July	BUDGET August	BUDGET September	BUDGET October	BUDGET November	BUDGET December	BUDGET Total		Ready Check
Invoice Sales										\$8,830,000	\$18,130,000	\$7,850,000	\$29,400,000	100.00%	
Deductions								-	-				\$0	0.00%	
Invoiced Sales Provision													\$0	0.00%	
Inv.Liquidations/Rollbacks													\$0	0.00%	
Returns & Allowances Provision													\$0	0.00%	
Special Discounts													\$0	0.00%	
TRADE SALES	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 8,830,000	\$ 18,130,000	\$ 7,350,000	\$ 29,400,000	100.00%	
Rebates													-	0.00%	
Rebates Provision													-	0.00%	
CO-OP Advertising													-	0.00%	
Cash Discounts													-	0.00%	
Cash Discounts Provision													-	0.00%	
NET SALES	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 8,830,000	\$ 18,130,000	\$ 7,350,000	\$ 29,400,000	100.00%	
Company Legal Set Up	12,000												12,000	0.04%	
Attorneys Cost	1,250												1,250	0.00%	
Legal Patent Register	5300												5,300	0.02%	
Patent Rights Fee													-	0.00%	
Trademark Legal Register	747												747	0.00%	
Imports Freight(Std. Cost)													-	0.00%	
Pending Liabilities	3270												-	0.00%	
Insurance													-	0.00%	
Provision for Excess & Obsolete													-	0.00%	
Capitalized Variances													-	0.00%	
Purchase Discount													-	0.00%	
Standard Cost of Goods Sold				120,540	120,540		120,340	700,900	1,154,979	641,005			2,942,940	10.01%	
TRADE SALES EXPENSES													-	0.00%	
Distribution Expense										264,000	300,000	220,500	802,000	3.00%	
National Freight										264,000	300,000	220,500	802,000	3.00%	
Inv. Std. Adj.													-	0.00%	
Other Cost of Goods Sold													-	0.00%	
CEDES										264,000	300,000	220,500	802,000	3.00%	
Other Cost of Goods Sold													-	0.00%	
COST OF SALES	\$ 22,075	\$ -	\$ -	\$ 120,540	\$ 120,540	\$ -	\$ 120,340	\$ 700,900	\$ 1,154,979	\$ 1,700,005	\$ 1,100,700	\$ 661,500	\$ 5,872,037	19.98%	
GROSS INCOME	\$ (22,075)	\$ -	\$ -	\$ (120,540)	\$ (120,540)	\$ -	\$ (120,340)	\$ (700,900)	\$ (1,154,979)	\$ 7,119,945	\$ 10,030,300	\$ 6,688,500	\$ 23,527,163	80.02%	
	#1 DNV01	#1 DNV01	#1 DNV01	#1 DNV01	#1 DNV01	#1 DNV01	#1 DNV01	#1 DNV01	#1 DNV01	80.7%	91.0%	91.0%	80.0%		
R&D Salaries	10,007	10,007	10,007	10,007	10,007	10,007	10,007	10,007	10,007	10,007	10,007	10,007	200,000	0.68%	
R&D Expenses	033	033	033	033	033	033	033	033	033	033	033	033	10,000	0.03%	
Corporate Assistant													0	0.00%	
COO Salaries	15,000	15,000	15,000	15,000	15,000	15,000	15,000	15,000	15,000	15,000	15,000	15,000	180,000	0.61%	
COO Expenses	750	750	750	750	750	750	750	750	750	750	750	750	9,000	0.03%	
Project Manager Salary													0	0.00%	
Project Manager Expenses													0	0.00%	
DESIGN & Mktng. Salary	2,000	2,000	2,000	2,000	2,000	2,000	2,000	2,000	2,000	2,000	2,000	2,000	24,000	0.08%	
DESIGN & Mktng. Expenses	500	500	500	500	500	500	500	500	500	500	500	500	6,000	0.02%	
Electric Engineering Salary			2,500	2,500	2,500	2,500	2,500	2,500	2,500	2,500	2,500	2,500	25,000	0.09%	
Electric Engineering Expenses			125	125	125	125	125	125	125	125	125	125	1,250	0.00%	
Outsourcing Other													0	0.00%	
Administrative	500	500	500	500	500	500	500	500	500	500	500	500	6,000	0.02%	
TOTAL SG&L	36,250	36,250	36,075	36,075	36,075	36,075	36,075	36,075	36,075	36,075	36,075	36,075	461,250	1.57%	
IT/Development & Admin. Expenses													-	0.00%	
Marketing									211,000	317,020	170,400		705,000	2.40%	
Advertising									299,000	449,020	240,000		990,000	3.40%	
Bonus													-	0.00%	
Bad Debt													-	0.00%	
Accountability													-	0.00%	
Financial Cost	415	415	415	2,075	2,075	2,075	4,150	41,500	41,500	41,500	41,500	41,500	210,120	0.73%	
TOTAL OPERATING EXPENSES	36,665	36,665	36,290	40,950	40,950	40,950	43,025	80,375	991,935	847,715	506,675	80,375	2,385,570	8.11%	
OPERATING INCOI	-\$59,340	-\$36,665	-\$39,290	-\$161,490	-\$161,490	-\$40,950	-\$178,365	-\$669,361	-\$1,746,914	\$6,272,290	\$11,532,625	\$6,688,125	\$21,141,593	71.91%	
	#1 DNV01	#1 DNV01	#1 DNV01	#1 DNV01	#1 DNV01	#1 DNV01	#1 DNV01	#1 DNV01	#1 DNV01	71.1%	87.2%	89.9%	71.91%		
EX.Currency	\$ 19.1700	\$ 19.2500	\$ 19.3300	\$ 19.4400	\$ 19.5000	\$19.6700	\$19.8200	\$19.8300	\$19.9300	\$20.0000	\$20.0900	\$20.1100	\$20.2200		



First Three Years Plan





SUMMARY

- 1 Big Opportunity to help humanity to heal**
The United States would be the pioneer in using this Groundbreaking treatment.
- 2 Powerful Market Validation**
More than 80 million potential treatment users only considering the U.S.
- 3 Simple Business Model**
Simple transaction driven model
- 4 Strong Scalability**
Gross margin above 70%.
- 5 Successful and Experienced Team**
Recognized professionals, experts in various areas of the business.



NEUVOLUTION Inc.
Pitch Deck MAY
2023

THANKS!